{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-270898","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.106554+00:00","generated_at":"2026-06-08T21:11:07.524867+00:00","sec_items":["1.01","2.01","2.02","3.02","3.03","4.01","5.01","5.02","5.03","5.05","5.07","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Frequency closes reverse merger with Korro Bio; combined entity renamed Korro Bio, Inc.","bullets":["Legacy Korro stockholders own ~91% of combined company; pre-closing financing raised $117.3M at ~$2.78/share.","1-for-50 reverse stock split effective Nov 3, 2023; ~738,526 pre-split shares became ~8.0M post-Merger shares outstanding.","New CEO Ram Aiyar; board reconstituted with 6 directors; Nessan Bermingham appointed Chair.","Auditor changed from RSM US LLP to Ernst & Young LLP; CVR agreement created for MS program asset proceeds.","Common stock begins trading on Nasdaq Capital Market under KRRO on Nov 6, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-270898","json":"https://secwatch.observer/filing/0001193125-23-270898.json","markdown":"https://secwatch.observer/filing/0001193125-23-270898.md","text":"https://secwatch.observer/filing/0001193125-23-270898.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/0001193125-23-270898-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/d549338d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T21:11:07.524867+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7b111795eb6531c338c7d2693caf872e21b0684a","claim":"Korro Bio, Inc. engaged Ernst & Young LLP as its auditor.","evidence_excerpt":"Appointment of New Independent Registered Public Accounting Firm Ernst & Young LLP, or E&Y, served as the independent registered public accounting firm of Legacy Korro prior to the completion of the Merger.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/0001193125-23-270898-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"engagement"},{"label":"Auditor","value":"Ernst & Young LLP"}],"fact_type":"auditor_change"},{"claim_id":"f5061dc6603d0fed0a942ccebe7ec8017c7d8eaf","claim":"Korro Bio, Inc. dismissed RSM US LLP as its auditor.","evidence_excerpt":"On November 3, 2023, following the completion of the Merger, RSM was dismissed as our independent registered public accounting firm.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/0001193125-23-270898-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"dismissal"},{"label":"Auditor","value":"RSM US LLP"},{"label":"Successor","value":"Ernst & Young LLP"}],"fact_type":"auditor_change"},{"claim_id":"06c366d166","claim":"Nessan Bermingham was appointed as Chairperson of the Board at Korro Bio, Inc..","evidence_excerpt":"Nessan Bermingham was appointed Chairperson of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/0001193125-23-270898-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairperson of the Board"}],"fact_type":"executive_change"},{"claim_id":"41c98efcf6","claim":"Jean-Francois Formela was appointed as Director at Korro Bio, Inc..","evidence_excerpt":"Ram Aiyar, Ali Behbahani, Nessan Bermingham and Jean-Francois Formela (designated by Legacy Korro)","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/0001193125-23-270898-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"4982d773a6","claim":"Ram Aiyar was appointed as Director at Korro Bio, Inc..","evidence_excerpt":"Ram Aiyar, Ali Behbahani, Nessan Bermingham and Jean-Francois Formela (designated by Legacy Korro)","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/0001193125-23-270898-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"5ce94cf113","claim":"David Lucchino resigned as President and Chief Executive Officer at Korro Bio, Inc..","evidence_excerpt":"Immediately after closing of the Merger, David Lucchino, resigned as our President and Chief Executive Officer and principal executive officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/0001193125-23-270898-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"917570f484","claim":"Ali Behbahani was appointed as Director at Korro Bio, Inc..","evidence_excerpt":"Ram Aiyar, Ali Behbahani, Nessan Bermingham and Jean-Francois Formela (designated by Legacy Korro)","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/0001193125-23-270898-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ac0d7d4c64","claim":"David Lucchino was appointed as Director at Korro Bio, Inc..","evidence_excerpt":"the Board was reconstituted as follows: (i) David L. Lucchino (designated by Frequency)","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/0001193125-23-270898-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ac5507e0ce","claim":"Cynthia L. Feldmann resigned as Director at Korro Bio, Inc..","evidence_excerpt":"Timothy J. Barberich, Cynthia L. Feldmann, Michael Huang and Robert S. Langer resigned from the Board and committees of the Board on which they respectively served","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/0001193125-23-270898-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d262caa18a","claim":"Robert S. Langer resigned as Director at Korro Bio, Inc..","evidence_excerpt":"Timothy J. Barberich, Cynthia L. Feldmann, Michael Huang and Robert S. Langer resigned from the Board and committees of the Board on which they respectively served","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/0001193125-23-270898-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d63ce5147c","claim":"Timothy Pearson was appointed as Director at Korro Bio, Inc..","evidence_excerpt":"Timothy Pearson (designated by mutual agreement)","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/0001193125-23-270898-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e56525c98d","claim":"Timothy J. Barberich resigned as Director at Korro Bio, Inc..","evidence_excerpt":"Timothy J. Barberich, Cynthia L. Feldmann, Michael Huang and Robert S. Langer resigned from the Board and committees of the Board on which they respectively served","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/0001193125-23-270898-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"eb8b3c929d","claim":"Michael Huang resigned as Director at Korro Bio, Inc..","evidence_excerpt":"Timothy J. Barberich, Cynthia L. Feldmann, Michael Huang and Robert S. Langer resigned from the Board and committees of the Board on which they respectively served","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/0001193125-23-270898-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ee221e664c","claim":"Ram Aiyar was appointed as Chief Executive Officer at Korro Bio, Inc..","evidence_excerpt":"Ram Aiyar, Ph.D., M.B.A. Dr. Aiyar has served as our Chief Executive Officer and a director since completion of the Merger.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/0001193125-23-270898-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"8d3d5a7b67a1db79cd050b171e9eee445a9504d1","claim":"Korro Bio, Inc.: Amended and restated the Code of Conduct and Ethics in connection with the Merger.","evidence_excerpt":"the Board amended and restated our Code of Conduct and Ethics.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/0001193125-23-270898-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"code of ethics"}],"fact_type":"governance_change"},{"claim_id":"b091d1e7b97edeac49baf3392a343e132e8988d3","claim":"Korro Bio, Inc.: Filed a second certificate of amendment to change the company name to 'Korro Bio, Inc.', effective upon filing on November 3, 2023 (effective 2023-11-03).","evidence_excerpt":"we filed a second certificate of amendment to the Charter","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/0001193125-23-270898-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-11-03"}],"fact_type":"governance_change"},{"claim_id":"cac34a28eb2e1fd87d7973bfc6b62653f53eb688","claim":"Korro Bio, Inc.: Approved and filed a certificate of amendment to effect a 1:50 reverse stock split, effective upon filing on November 3, 2023 (effective 2023-11-03).","evidence_excerpt":"stockholders approved an amendment to our restated certificate of incorporation","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/0001193125-23-270898-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-11-03"}],"fact_type":"governance_change"},{"claim_id":"3bfb2791bc11400f44fc6af7ebd02409b6e664df","claim":"Korro Bio, Inc. underwent a change of control involving Korro Bio, Inc. (Legacy Korro) (closed 2023-11-03).","evidence_excerpt":"On November 3, 2023, we completed the previously announced business combination with Legacy Korro in accordance with the terms of the Merger Agreement, pursuant to which, among other matters, Merger Sub merged with and into Legacy Korro, with Legacy Korro surviving as our wholly owned subsidiary (such business combination, the Merger).","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/0001193125-23-270898-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Korro Bio, Inc. (Legacy Korro)"},{"label":"Closing","value":"2023-11-03"}],"fact_type":"ma_transaction"},{"claim_id":"02f3249fa69563bcf442c4dc6ca7324d5399b2ff","claim":"Korro Bio, Inc. shareholders approved Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposals 1 and 2 at the 2023-11-03 meeting.","evidence_excerpt":"Proposal 7 - Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposals 1 and 2. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 10,980,682 808,960 324,296 11,937,522","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/0001193125-23-270898-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-03"}],"fact_type":"shareholder_vote"},{"claim_id":"09aa0f7937099dfe41078d85950a4efc4e8f22a0","claim":"Korro Bio, Inc. shareholders approved Approval of the amendment to the Charter effecting the reverse stock split at the 2023-11-03 meeting.","evidence_excerpt":"Proposal 2 - Approval of the amendment to the Charter effecting the reverse stock split. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 22,748,459 1,021,963 281,038 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/0001193125-23-270898-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-03"}],"fact_type":"shareholder_vote"},{"claim_id":"3c8ac53bdd75699cee7f992c3498a8d0892a024d","claim":"Korro Bio, Inc. shareholders approved Approval of the issuance of common stock in the Merger and the change in control resulting from the Merger at the 2023-11-03 meeting.","evidence_excerpt":"Proposal 1 - Approval of the issuance of common stock in the Merger and the change in control resulting from the Merger. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 11,505,632 383,292 225,014 11,937,522","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/0001193125-23-270898-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"merger approval"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-03"}],"fact_type":"shareholder_vote"},{"claim_id":"602f3785e6b8992384d37cc87c9e0e7a410a67c4","claim":"Korro Bio, Inc. shareholders approved Approval of the Korro Bio, Inc. 2023 Stock Option and Incentive Plan at the 2023-11-03 meeting.","evidence_excerpt":"Proposal 5 - Approval of the Korro Bio, Inc. 2023 Stock Option and Incentive Plan. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 6,321,270 5,464,618 328,050 11,937,522","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/0001193125-23-270898-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-03"}],"fact_type":"shareholder_vote"},{"claim_id":"8204d9aeee03da4499a5636645c72d6ea1ff9b03","claim":"Korro Bio, Inc. shareholders approved Ratification of the appointment of RSM US LLP as our independent registered public accounting firm for the year ending December 31, 2023 at the 2023-11-03 meeting.","evidence_excerpt":"Proposal 4 - Ratification of the appointment of RSM US LLP as our independent registered public accounting firm for the year ending December 31, 2023. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 23,049,119 329,237 673,104 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/0001193125-23-270898-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-03"}],"fact_type":"shareholder_vote"},{"claim_id":"a1625533863b9cbe760fca5011d97d5ff3ed8d97","claim":"Korro Bio, Inc. shareholders approved Approval of the Korro Bio, Inc. 2023 Employee Stock Purchase Plan at the 2023-11-03 meeting.","evidence_excerpt":"Proposal 6 - Approval of the Korro Bio, Inc. 2023 Employee Stock Purchase Plan. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 8,145,970 3,641,499 326,369 11,937,522","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/0001193125-23-270898-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-03"}],"fact_type":"shareholder_vote"},{"claim_id":"e2252385f75a16fdacdebb8ab832e6cb4c89d7c0","claim":"Korro Bio, Inc. shareholders approved Election of one Class I director to serve until the 2026 Annual Meeting of Stockholders, and until his successor has been duly elected and qualified at the 2023-11-03 meeting.","evidence_excerpt":"Proposal 3 - Election of one Class I director to serve until the 2026 Annual Meeting of Stockholders, and until his successor has been duly elected and qualified. NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes David L. Lucchino 9,100,124 3,013,814 11,937,522","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/0001193125-23-270898-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-03"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}